Congratulations! The GCP inspection of phase I cell therapy study for chronic stroke was approval by TFDA
UPDATE : 2019/09/03
Virginia Contract Research Organization Co., Ltd.(VCRO) has successfully conducted and managed the clinical operation, data management, statistical analysis, medical writing, and GCP inspection of a phase I cell therapy IND-used study. In this clinical trial, VCRO has conquered diverse challenges the fast-paced nature of an cell therapy study, and overcame all the difficulties. On Sep-2019, the study was granted with an approval by TFDA for the GCP inspection. Just another epic VCRO milestone that we are excited to share with you!